Lecture Series
Meeting Information From the Group
For Closed Captions, start the video and click CC at the bottom.
The GSA KAER Toolkit for Brain Health
Jennifer Pettis, MS, RN, CNE
Acceptable Performance of Blood Biomarker Tests of Amyloid Pathology - Recommendations from the Global CEO Initiative on Alzheimer's Disease
Suzanne E. Schindler, MD, PhD
5/16/2024 FDA Guidance: Early Alzheimer's Disease: Developing Drugs for Treatment
Nadezda Radoja, PhD
5/16/2024 Harding Center for Risk Literacy: Study of How People Behave in Situations of Risk and Uncertainty
Felix G. Rebitschek, PhD
A Delphi Study to Develop Stakeholder Consensus Regarding Sharing Individual Research Results in ADRD Research
Lauren Sankary, JD, MA
Alzheimer's Clinical Trial Consortium Research Participant Advisory Board
Sarah Walter, MSc
Obstacles to Equitable and Timely Access to New Alzheimer Disease Diagnostics and Treatments
Suzanne E. Schindler, MD, PhD
Testing the Feasibility and Acceptability of Using Plasma Biomarkers for Diagnosing Alzheimer's Disease in Primary Care
Nicole R. Fowler, PhD, M
Davos Alzheimer's Collaborative
Tim MacLeod, PhD
The Global CEO Initiative on Alzheimer's Disease
Emily Scholler, MPH
The Intersection of Direct-to-Consumer Testing & Dementia
Jalayne Arias, JD, MA
Brain Watch Coalition
Brittany Cassin, MBA and Ara S. Khachaturian,
Ph.D.
The Wild West of Alzheimer Disease Blood Tests
Suzanne E. Schindler, MD, PhD
Bio-Hermes-001 and Biomarker Assessment Against a Gold Standard
Suzanne
Hendrix, PhD & Jenn Gaudioso,
BS
Lecanemab for Early Alzheimer's Disease:
ICER's Review and Policy Implications
Grace Lin, MD
Preparing the Healthcare System to Support Timely Diagnosis and Treatment for AD
Pei-Jung (Paige) Lin, PhD
Pathways to Well-Being with Dementia
Rev. Dr. Cynthia Huling Hummel
Regulatory Landscape for Biomarkers Development:
Relevance for AD/ADRD Research and Therapy Development
Nadezda Radoja, PhD
Global CEO Initiative on AD Blood-Based Biomarker Working Group
Katie Partrick, PhD
The GSA KAER Toolkit for Primary Care Teams
Karen K. Tracy, BS and Jennifer L. Pettis, MS
Sequential Administration of DIGItal Testing in the Primary Care Setting to Screen for Cognitive Impairment Followed by Blood Based Biomarkers to Assist with Timely Detection and Accurate Diagnosis of ALzheimer's Disease at Indiana University (IU) and IU Health (IUH)
Nicole Fowler, PhD
Considering a Framework for Return of Individual Research Results
Barbara E. Bierer, MD
Blood Tests for Alzheimer's Disease
Thomas Karikari, PhD
Considerations Regarding a Diagnosis of AD Based on Biomarkers
Jetske van der Schaar, MS
FDA Market Authorization of the Lumipulse® G β-Amyloid Ratio (1-42/1-40) Test
Rianne Esquivel, PhD
Overview: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Plans For ADNI4 Improving Generalizability by Increasing Diversity
Michael Weiner, MD
Development of Algorithm to Calculate 5 Year Absolute Risk of AD
Sarah Hartz, MD, PhD and Jessica Mozersky, PhD
Sharing Biomarker Results with Cognitively Healthy Research Participants
Lindsay Clark, PhD
Update on Status of Blood-Based Markers for Alzheimer's Disease:
Readiness for Clinical Use
Michelle M. Mielke, PhD
Biofluid Biomarkers of Neuropsychiatric Symptoms in Dementia with
Lewy Bodies & Alzheimer's Disease
Fabricio Oliveira, MD, PhD
Dementia in the Borderlands
Gladys Maestre, MD, PhD
Aducanumab: Where do we go from here?
Joshua Grill, PhD
The Next Steps Towards Precision Medicine in Parkinson's Disease
Ron Alcalay, MD
Communicating 5 Year Risk of AD Dementia Based on Multiple Research Results to a Longitudinal Cohort of Healthy Older Adults
Jessica Mozersky, PhD
Overcoming Stigma
Rev. Dr. Cynthia Huling Hummel
Results from the Study of Knowledge and Reactions to Amyloid Testing (SOKRATES)
Emily A. Largent, JD, PhD
The First Blood Test for Alzheimer Disease is Now Available for Clinical Use
Suzanne Schindler, MD
Utilization of Cerebrospinal Fluid Biomarkers for the Detection
of Alzheimer's Disease in Mild Cognitive Impairment
and Subjective Cognitive Decline in Routine Clinical Care in Germany
Anja Schneider, MD
Deepening Stakeholder Engagement through attendance of
a virtual Scientific Conference
Sarah Walter, MSc
Asian Cohort for Alzheimer's Disease Study
Li-San
Wang, PhD
Legal Protections and Vulnerabilities from Genetic and Biomarkers
Jalayne Arias, JD
Return of Genomic Results in All of Us
Robert C. Green, MD
Ethics in the European Prevention of Alzheimer's Dementia (EPAD) project
Richard Milne, PhD
MRI Face Recognition and De-Identification
Christopher Schwartz, PhD
COVID-19 Issues
Robyn S. Shapiro, JD
Effects of Advances in Biomarker-Based Diagnosis and Disease-Modifying Treatment on Alzheimer's Disease Stigma
Shana D. Stites, PsyD
VISN 17 Center of Excellence for Research on Returning War Veterans
Laura Zambrano-Vazquez, PhD
Upcoming Speakers